Gilead's magrolimab once again placed on partial clinical hold, another setback for Forty Seven bet

Exactly a month after Gilead Sciences revealed it had shelved a myelodysplastic syndromes (MDS) program for magrolimab, the molecule has been placed under a partial clinical hold by the FDA for its phase 3 acute myeloid leukemia (AML) studies.